Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Free Report) – Stock analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for shares of Armata Pharmaceuticals in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.95) per share for the year, up from their previous forecast of ($1.02). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2024 earnings at ($0.35) EPS and FY2025 earnings at ($1.70) EPS.
Armata Pharmaceuticals Price Performance
NYSEAMERICAN:ARMP opened at $2.41 on Monday. The firm has a market cap of $87.19 million, a P/E ratio of -1.47 and a beta of 0.80. Armata Pharmaceuticals has a 52 week low of $1.93 and a 52 week high of $4.48.
Armata Pharmaceuticals Company Profile
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Featured Stories
- Five stocks we like better than Armata Pharmaceuticals
- How to Most Effectively Use the MarketBeat Earnings Screener
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- What Investors Need to Know to Beat the Market
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Using the MarketBeat Stock Split Calculator
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.